ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0291

Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients

Naga Prabu1, velammal petchaippan2, Gayathri anand3, Aswathi kumar1 and Saranya Ramachandiran3, 1SAKTHI RHEUMATOLOGY CENTRE PVT LTD, Coimbatore, India, 2PSG INSTTUTE OF MEDICAL SCIENCES AND RESEARCH, Coimbatore, India, 3sakthi rheumatology centre pvt l;td, Coimbatore, India

Meeting: ACR Convergence 2022

Keywords: Biologicals, Drug toxicity, metabolic syndrome, obesity, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Treatment Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Tofacitinib(Tofa) an oral Janus kinase inhibitor(JAK) has shown good promise in the management of rheumatoid arthritis and psoriatic arthritis. While being increasingly used in the management of rheumatoid arthritis in view of the ease of administration and reduction of cost after the patent period, it’s being more commonly used /misused by both rheumatologist and non rheumatologist. While the known adverse events of infections (herpes zoster flare up) and cardiovascular events are evident after the clinical trial results, there was an observational study which mentioned weight gain as a prominent adverse event after tofacitinib therapy

Methods: We retrieved patients records who were prescribed tofacitinib for various indications (rheumatoid arthritis , psoriatic arthritis,spondyloarthritis ) from January 2020 to December 2021.Demographics,comorbid illness,body weight (kilograms),mean duration of tofa intake, concomitant drugs, adverse events and lab investigations were taken for analysis. Patients with no follow-up records, no weight recordings and with less than 6 months follow-up were excluded.

Results: There were a total of 693 patients out of which 429 patients fulfilled the inclusion criteria.There were 377 RA patients and 52 with spondyloarthritis.Of the 429 patients, 292(68%) had weight gain,107(25%) had weight loss and 30(7%) had no change in weight.In RA subgroup 255(68%) had weight gain; 94(25%) had weight loss and 28(7%) had no change in weight. In spondyloarthritis subgroup 37(71%) had weight gain;13((25%) had weight loss and 2(4%)had no change in weight .There was a significant gain in weight of 1.65(0.47)kg in the entire cohort. Spondyloarthritis group had relatively more gain in weight(kg) 2.57(1.11) than RA patients 1.52(0.52)

Conclusion: Tofacitinib leads to significant weight gain in 68% of study patients which is more with Spondyloarthritis than Rheumatoid arthritis. Physician’s prescribing tofacitinib should take this into consideration.

Supporting image 1


Disclosures: N. Prabu, None; v. petchaippan, None; G. anand, None; A. kumar, None; S. Ramachandiran, None.

To cite this abstract in AMA style:

Prabu N, petchaippan v, anand G, kumar A, Ramachandiran S. Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/tofacitinib-leads-to-significant-weight-gain-a-real-life-experience-of-429-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tofacitinib-leads-to-significant-weight-gain-a-real-life-experience-of-429-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology